Peritoneal neoplasm – Diagnostics – Overview of Information and Clinical Research

Diagnosing peritoneal neoplasm requires a careful combination of physical examination, imaging studies, blood tests, and sometimes surgical procedures to confirm the presence of cancer cells in the delicate membrane lining the abdomen.

Introduction: Who Should Undergo Diagnostics

Peritoneal neoplasm, or cancer affecting the peritoneum—the thin tissue lining the inside of the abdomen—often develops silently. Most people do not notice symptoms until the disease has progressed to an advanced stage. Because early symptoms are vague and easily confused with other common conditions like irritable bowel syndrome or digestive problems, knowing when to seek medical attention becomes crucial.^[1]

You should consider seeking diagnostic evaluation if you experience persistent abdominal symptoms that don’t improve with time. These warning signs include ongoing abdominal swelling or bloating, unexplained abdominal pain or pressure, feeling full quickly after eating small amounts, persistent changes in bowel habits, or unexplained weight changes. Women should be particularly alert to these symptoms, as they may also experience abnormal vaginal bleeding or frequent urination.^[3]

Certain people face higher risk and should be especially vigilant. If you have a family history of peritoneal, ovarian, or fallopian tube cancer, you may need earlier or more frequent monitoring. Women who carry BRCA1 or BRCA2 gene mutations—changes in genes that normally help prevent cancer—have significantly increased risk. People who have already been diagnosed with cancers in nearby organs, such as the ovaries, colon, stomach, appendix, or pancreas, should also undergo careful monitoring, as peritoneal cancer often develops when cancer spreads from these organs.^[1]^[4]

Age also matters. Most people diagnosed with peritoneal cancer are over 60 years old, and women are affected more frequently than men. Additional risk factors include endometriosis, obesity, being taller than average, having no biological children, and using hormone replacement therapy after menopause. If you have any combination of these risk factors along with persistent symptoms, speaking with your doctor about diagnostic testing is advisable.^[11]

⚠️ Important

Many symptoms of peritoneal cancer overlap with less serious digestive conditions. However, if symptoms persist for more than a few weeks, worsen over time, or occur alongside other warning signs, do not dismiss them. Early consultation with a healthcare provider can make a significant difference, even though peritoneal cancer is often diagnosed at later stages due to its subtle early presentation.

Classic Diagnostic Methods

Diagnosing peritoneal neoplasm involves multiple approaches because the cancer often spreads across the abdominal lining without forming distinct, easily visible masses. Your healthcare provider will typically begin with a thorough review of your medical history and symptoms, followed by a complete physical examination. During the physical exam, the doctor will check your abdomen for swelling, fluid buildup, or any unusual masses. For women, this includes a pelvic examination to assess the uterus, ovaries, fallopian tubes, bladder, and rectum for abnormalities.^[4]^[8]

Imaging Tests

Imaging studies are usually the first step in looking for suspected peritoneal cancer. These tests create detailed pictures of the inside of your body, helping doctors identify tumor spread, fluid accumulation, or organ involvement. However, imaging alone is not always sensitive enough to detect smaller cancers or early peritoneal disease, so a negative scan does not completely rule out the condition.^[9]

Computed tomography (CT) scans are the most commonly used imaging method for peritoneal cancer. A CT scan uses X-rays and computer technology to create detailed cross-sectional images of your abdomen and pelvis. This test helps doctors see the extent of disease spread and assess whether tumors are present. CT scans are widely available, relatively affordable, and provide good sensitivity for detecting peritoneal cancer, making them the method of choice in most cases.^[4]^[6]

Magnetic resonance imaging (MRI) uses powerful magnets and radio waves instead of X-rays to create detailed images of soft tissues. The sensitivity of MRI depends on the size of peritoneal implants—for tumors larger than 10 millimeters, MRI performs comparably to CT scans. Some physicians may prefer MRI in certain situations because it provides excellent soft tissue detail without radiation exposure.^[12]

Positron emission tomography (PET) scans, often combined with CT (PET-CT), can detect cancer cells based on their increased metabolic activity. Some studies suggest that PET-CT may be the most sensitive method for finding peritoneal cancer. However, its usefulness in everyday practice remains controversial, and it is not routinely used for initial diagnosis in all patients. PET-CT may be more helpful in specific situations, such as monitoring treatment response or detecting cancer recurrence.^[6]^[12]

Ultrasound, which uses high-frequency sound waves to create images, plays only a marginal role in diagnosing peritoneal cancer because of its low sensitivity and specificity. However, ultrasound may be useful for detecting fluid in the abdomen or examining the ovaries as part of the initial evaluation.^[4]^[12]

Blood Tests

Blood tests cannot definitively diagnose peritoneal cancer, but they provide important supporting information. The CA-125 test measures levels of a protein called cancer antigen 125 in the blood. Elevated CA-125 levels may indicate peritoneal or ovarian cancer, but this test is not conclusive because CA-125 can also be elevated in other conditions, including non-cancerous ones. Therefore, high CA-125 alone cannot confirm a cancer diagnosis, but it can raise suspicion and guide further testing.^[4]^[8]

Newer blood tests look for circulating tumor DNA (ctDNA)—small pieces of DNA released by cancer cells into the bloodstream. These tests can sometimes detect peritoneal cancer that doesn’t show up on imaging scans. While promising, ctDNA testing is still relatively new and may not be universally available yet.^[9]

Fluid Analysis

When fluid accumulates in the abdomen—a condition called ascites—doctors can collect and analyze it. The procedure to remove this fluid is called paracentesis. During paracentesis, a needle is inserted through the abdominal wall to withdraw a sample of fluid. Laboratory technicians then examine the fluid under a microscope to check for cancer cells.^[6]

Peritoneal washing cytology is a more specialized version of fluid analysis. During a minor surgical procedure, fluid from the abdominal cavity is collected and examined microscopically. Even when no visible cancer is present, finding cancer cells floating in the peritoneal fluid is a strong sign that cancer has spread to the peritoneum. This test is especially valuable because it can detect cancer that imaging cannot see.^[9]

Surgical Procedures for Diagnosis

Staging laparoscopy is a minimally invasive surgical procedure that allows doctors to look directly inside the abdominal cavity using a small camera. Through tiny incisions in the abdomen, surgeons insert a thin tube with a camera attached, letting them inspect the peritoneum, locate hidden tumors, and collect tissue or fluid samples for testing. This procedure is especially valuable for finding peritoneal cancer that is too small to be seen on imaging scans. Staging laparoscopy is considered safe and provides definitive information about whether cancer is present and how far it has spread.^[9]

Biopsy involves removing a small sample of tissue from a suspected tumor so it can be examined under a microscope. Biopsies can be performed during laparoscopy or other surgical procedures. Laboratory analysis of biopsy tissue confirms whether cancer cells are present and helps identify the type and origin of cancer. This information is critical for planning treatment.^[6]^[8]

Peritoneal Carcinomatosis Index

The Peritoneal Carcinomatosis Index (PCI) is a standardized scoring system used to assess how much tumor is present in the peritoneum. During surgical examination, doctors divide the abdomen into 13 regions and score each region based on the size of tumors found there. The total score helps predict whether surgery can successfully remove all visible cancer and assists in planning treatment. The PCI also serves as a communication tool between surgeons, oncologists, and other members of the healthcare team.^[12]^[21]

⚠️ Important

Peritoneal cancer often spreads across the abdominal lining without forming distinct masses, which makes diagnosis challenging. Doctors usually need to combine multiple approaches—imaging, fluid tests, blood tests, and sometimes surgery—to confirm the diagnosis. A single negative test does not rule out peritoneal cancer, so persistent symptoms warrant continued investigation.

Diagnostics for Clinical Trial Qualification

When considering enrollment in clinical trials for peritoneal neoplasm, patients typically undergo additional or more detailed diagnostic testing beyond standard clinical evaluation. Clinical trials have specific eligibility criteria that must be documented through standardized tests to ensure patient safety and valid research results.

Imaging studies form the foundation of clinical trial qualification testing. Most trials require recent CT scans or MRI studies of the abdomen and pelvis, usually performed within a few weeks of potential enrollment. These images must clearly document the presence, location, and extent of peritoneal disease. Some trials may also require PET-CT scans to better characterize metabolic activity of tumors or to rule out disease spread beyond the peritoneum.^[6]

Blood tests for tumor markers are commonly required. Beyond standard CA-125 testing, some trials may measure other markers depending on the primary cancer type. Trials testing new targeted therapies often require genetic testing of tumor tissue to identify specific mutations or biomarkers that predict treatment response. For example, trials involving patients with peritoneal cancer who carry BRCA mutations may require documented genetic testing results confirming the presence of these mutations.^[13]

Tissue biopsy is frequently necessary for clinical trial enrollment. Fresh tumor tissue may be required to perform specialized tests, such as identifying specific protein expressions or genetic alterations that make a patient eligible for particular targeted treatments. In some cases, archived tissue from previous biopsies may be acceptable, but many trials prefer newly obtained samples to ensure accurate, current information about the cancer.^[13]

Performance status assessment is another standard requirement. Doctors evaluate how well you can perform daily activities using standardized scales. Most clinical trials only accept patients who are well enough to tolerate experimental treatments, so documentation of good physical function is essential.

Laboratory tests measuring overall health are universally required. These include complete blood counts to assess bone marrow function, liver function tests, kidney function tests, and other measurements ensuring that vital organs can handle the proposed treatment. Abnormal results in these tests may disqualify a patient from certain trials or require medical optimization before enrollment.

Some trials studying new diagnostic or monitoring techniques may require additional specialized tests not used in routine clinical practice. For example, trials evaluating liquid biopsy technologies may collect extra blood samples specifically for research purposes. Trials investigating new imaging agents may perform experimental scans beyond standard clinical imaging.

The specific diagnostic requirements vary considerably depending on the trial design, the treatment being studied, and the stage of research. Early-phase trials testing completely new treatments often have stricter requirements and may need more extensive testing compared to later-phase trials studying treatments already shown to be safe. Your oncology team can explain exactly which tests are needed for any specific trial you might consider.

Prognosis and Survival Rate

Prognosis

The outlook for peritoneal neoplasm depends on several important factors. Whether the cancer started in the peritoneum (primary peritoneal cancer) or spread there from another organ (secondary peritoneal cancer) affects prognosis. The stage at diagnosis matters significantly—peritoneal cancer is usually diagnosed at later stages because early symptoms are vague and often go unnoticed. People diagnosed at earlier stages generally have better outcomes than those diagnosed after the cancer has spread extensively.^[1]

The type of primary cancer that spread to the peritoneum influences prognosis. For example, peritoneal cancer arising from ovarian cancer may have different outcomes compared to cancer spreading from the colon or stomach. The amount of tumor burden in the peritoneum, often measured by the Peritoneal Carcinomatosis Index, helps predict outcomes. Patients with lower tumor burden who can undergo complete surgical removal of visible cancer tend to have better prognoses.^[12]

Patient-related factors also play a role. Overall health, age, and the ability to tolerate intensive treatments like surgery and chemotherapy affect outcomes. People with better physical function and fewer other medical conditions generally have improved survival. The presence of certain genetic mutations, such as BRCA1 or BRCA2, may influence both disease behavior and treatment options. For example, BRCA mutation carriers may respond better to certain targeted therapies.^[13]

Treatment response matters greatly. The effectiveness of cytoreductive surgery—an operation to remove all visible cancer—combined with heated intraperitoneal chemotherapy (HIPEC) has significantly improved outcomes for select patients. When surgeons can remove all or nearly all visible tumor, prognosis improves considerably. However, not all patients are candidates for these intensive procedures. The prognosis for peritoneal cancer is generally considered worse than that of ovarian cancer, and people with peritoneal cancer tend to be older at diagnosis.^[1]^[11]

Survival rate

Survival statistics for peritoneal cancer vary widely depending on treatment and individual circumstances. Historically, with traditional therapeutic options, median survival ranged from approximately 4 to 12 months. However, the introduction of multimodality therapy—combining cytoreductive surgery with heated intraperitoneal chemotherapy—has shown promising results, with survival approaching 60 months for carefully selected patients who can undergo complete tumor removal.^[13]

It is important to understand that survival statistics represent averages from large groups of patients and may not predict any individual’s outcome. Many factors influence survival, including the specific type and extent of cancer, response to treatment, overall health, and advances in medical care. Some patients live much longer than average statistics suggest, especially with newer treatment approaches and personalized therapies. Your healthcare team can provide more specific information based on your individual situation.^[13]

#1 Clinical Trials Search in Europe